WO1994018221A1
(en)
*
|
1993-02-02 |
1994-08-18 |
The Scripps Research Institute |
Methods for producing polypeptide binding sites
|
DK0744958T3
(da)
|
1994-01-31 |
2003-10-20 |
Univ Boston |
Polyklonale antistofbiblioteker
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
DE69621940T2
(de)
*
|
1995-08-18 |
2003-01-16 |
Morphosys Ag |
Protein-/(poly)peptidbibliotheken
|
US6017754A
(en)
*
|
1995-08-24 |
2000-01-25 |
Invitrogen Corporation |
System for isolating and identifying eukaryotic cells transfected with genes and vectors, host cells and methods thereof
|
FR2741892B1
(fr)
*
|
1995-12-04 |
1998-02-13 |
Pasteur Merieux Serums Vacc |
Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
|
US6696251B1
(en)
*
|
1996-05-31 |
2004-02-24 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
GB9701425D0
(en)
*
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
US6596850B1
(en)
*
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
US6590079B2
(en)
*
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
EP0985033A4
(en)
*
|
1997-04-04 |
2005-07-13 |
Biosite Inc |
POLYVALENT AND POLYCLONAL LIBRARIES
|
US6057098A
(en)
*
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
GB9722131D0
(en)
*
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
US6759243B2
(en)
*
|
1998-01-20 |
2004-07-06 |
Board Of Trustees Of The University Of Illinois |
High affinity TCR proteins and methods
|
NZ508950A
(en)
|
1998-07-13 |
2003-10-31 |
Univ Texas |
Cancer treatment methods using antibodies to aminophospholipids
|
EP1100890A2
(en)
|
1998-07-27 |
2001-05-23 |
Genentech, Inc. |
Improved transformation efficiency in phage display through modification of a coat protein
|
US6531580B1
(en)
*
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
US20070111259A1
(en)
*
|
1999-10-02 |
2007-05-17 |
Medarex, Inc. |
Human antibodies
|
US6794132B2
(en)
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
US7135287B1
(en)
|
1999-10-02 |
2006-11-14 |
Biosite, Inc. |
Human antibodies
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
US6680209B1
(en)
*
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
CA2393869A1
(en)
*
|
1999-12-15 |
2001-06-21 |
Genetech,Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
ATE474854T1
(de)
*
|
2000-01-27 |
2010-08-15 |
Medimmune Llc |
Rsv neutralisierende antikörper mit sehr hohen affinität
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
CA2401652A1
(en)
|
2000-03-01 |
2001-09-07 |
Medimmune, Inc. |
High potency recombinant antibodies and method for producing them
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US6818216B2
(en)
*
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
WO2003004604A2
(en)
*
|
2001-07-06 |
2003-01-16 |
Genentech, Inc. |
Phage displayed pdz domain ligands
|
US20030104604A1
(en)
*
|
2001-08-03 |
2003-06-05 |
Weiping Yang |
Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
|
ATE434184T1
(de)
|
2001-11-20 |
2009-07-15 |
Univ Duke |
Grenzflächen-biomaterialien
|
GB0202206D0
(en)
*
|
2002-01-31 |
2002-03-20 |
Bioinvent Int Ab |
Method of making libraries of anti-ligands
|
US7504364B2
(en)
*
|
2002-03-01 |
2009-03-17 |
Receptors Llc |
Methods of making arrays and artificial receptors
|
US7244592B2
(en)
*
|
2002-03-07 |
2007-07-17 |
Dyax Corp. |
Ligand screening and discovery
|
US20030228302A1
(en)
*
|
2002-04-17 |
2003-12-11 |
Roberto Crea |
Universal libraries for immunoglobulins
|
US7405062B2
(en)
*
|
2002-05-14 |
2008-07-29 |
San Diego Antibody |
Method for cloning variable domain sequences of immunological gene repertoire
|
WO2003102157A2
(en)
*
|
2002-06-03 |
2003-12-11 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
KR20120068769A
(ko)
|
2002-07-15 |
2012-06-27 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
|
PT2314629E
(pt)
*
|
2002-07-18 |
2014-01-22 |
Merus B V |
Produção recombinante de misturas de anticorpos
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
WO2004010935A2
(en)
*
|
2002-07-25 |
2004-02-05 |
Medimmune, Inc. |
Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
US20050037429A1
(en)
*
|
2003-03-28 |
2005-02-17 |
Receptors Llc |
Artificial receptors including reversibly immobilized building blocks and methods
|
US20050037381A1
(en)
*
|
2002-09-16 |
2005-02-17 |
Receptors Llc |
Artificial receptors, building blocks, and methods
|
US20040137481A1
(en)
*
|
2002-09-16 |
2004-07-15 |
Receptors Llc |
Artificial receptor building blocks, components, and kits
|
US20050170385A1
(en)
*
|
2002-09-16 |
2005-08-04 |
Receptors Llc |
Artificial receptors including gradients
|
US7469076B2
(en)
*
|
2003-09-03 |
2008-12-23 |
Receptors Llc |
Sensors employing combinatorial artificial receptors
|
US20060057625A1
(en)
*
|
2002-09-16 |
2006-03-16 |
Carlson Robert E |
Scaffold-based artificial receptors and methods
|
US20050136483A1
(en)
*
|
2003-09-03 |
2005-06-23 |
Receptors Llc |
Nanodevices employing combinatorial artificial receptors
|
US20050037428A1
(en)
*
|
2002-09-16 |
2005-02-17 |
Receptors Llc |
Artificial receptors including reversibly immobilized building blocks, the building blocks, and methods
|
KR101388611B1
(ko)
|
2002-10-16 |
2014-04-23 |
퍼듀 퍼머 엘피 |
세포-연관된 ca 125/o772p에 결합하는 항체들 및 그것의 용도의 방법들
|
US20060134100A1
(en)
*
|
2002-11-05 |
2006-06-22 |
Ali Amara |
Dc-sign blockers and their use for preventing or treating viral infections
|
US7427469B2
(en)
*
|
2002-11-05 |
2008-09-23 |
Institut Pasteur |
Method of treating cytomegalovirus with DC-SIGN blockers
|
WO2004044161A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Fraunhofer Usa |
Expression of foreign sequences in plants using trans-activation system
|
US7692063B2
(en)
*
|
2002-11-12 |
2010-04-06 |
Ibio, Inc. |
Production of foreign nucleic acids and polypeptides in sprout systems
|
US7683238B2
(en)
*
|
2002-11-12 |
2010-03-23 |
iBio, Inc. and Fraunhofer USA, Inc. |
Production of pharmaceutically active proteins in sprouted seedlings
|
WO2004065416A2
(en)
*
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004070016A2
(en)
|
2003-02-03 |
2004-08-19 |
Fraunhofer Usa Inc. |
System for expression of genes in plants
|
US20050008625A1
(en)
*
|
2003-02-13 |
2005-01-13 |
Kalobios, Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
RU2005131852A
(ru)
|
2003-03-14 |
2006-04-20 |
Уайт (Us) |
Антитела против человеческого рецептора il-21 и их применение
|
EP1613737A4
(en)
*
|
2003-03-28 |
2008-12-03 |
Receptors Llc |
ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
|
BRPI0410562B8
(pt)
|
2003-05-22 |
2021-05-25 |
Fralunhofer Usa Inc |
proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
JP4716517B2
(ja)
|
2003-06-09 |
2011-07-06 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
神経変性疾患を治療する方法
|
WO2005011580A2
(en)
*
|
2003-07-25 |
2005-02-10 |
Board Of Regents, The University Of Texas System |
Compositions and methods for herpes simplex prophylaxis and treatment
|
AU2004261980A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody CDR polypeptide sequences with restricted diversity
|
US20070274988A1
(en)
*
|
2003-10-10 |
2007-11-29 |
Five Prime Therapeautics, Inc. |
Kiaa0779, Splice Variants Thereof, and Methods of Their Use
|
US7329725B1
(en)
*
|
2003-10-29 |
2008-02-12 |
Nastech Pharmaceutical Company Inc. |
Phage displayed Trp cage ligands
|
WO2005054438A2
(en)
|
2003-12-01 |
2005-06-16 |
Invitrogen Corporation |
Nucleic acid molecules containing recombination sites and methods of using the same
|
EP1761561B1
(en)
|
2004-01-20 |
2015-08-26 |
KaloBios Pharmaceuticals, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
ES2646560T3
(es)
|
2004-01-20 |
2017-12-14 |
Merus N.V. |
Mezclas de proteínas de unión
|
EP1769068B1
(en)
*
|
2004-02-20 |
2014-12-31 |
iBio, Inc. |
Systems and methods for clonal expression in plants
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
EP1789453A2
(en)
*
|
2004-05-18 |
2007-05-30 |
Genentech, Inc. |
M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
|
US7572766B2
(en)
|
2004-06-16 |
2009-08-11 |
Affinergy, Inc. |
IFBMs to promote the specific attachment of target analytes to the surface of orthopedic implants
|
BRPI0513135A
(pt)
|
2004-07-06 |
2008-04-29 |
Bioren Inc |
bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
|
US20060068421A1
(en)
*
|
2004-08-05 |
2006-03-30 |
Biosite, Inc. |
Compositions and methods for phage display of polypeptides
|
WO2006029234A1
(en)
|
2004-09-03 |
2006-03-16 |
Receptors Llc |
Combinatorial artificial receptors including tether building blocks
|
EP1789792A2
(en)
*
|
2004-09-11 |
2007-05-30 |
Receptors LLC |
Combinatorial artificial receptors including peptide building blocks
|
US20060115485A1
(en)
*
|
2004-10-29 |
2006-06-01 |
Medimmune, Inc. |
Methods of preventing and treating RSV infections and related conditions
|
DK3050963T3
(da)
|
2005-03-31 |
2019-12-09 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
|
EP1876236B9
(en)
*
|
2005-04-08 |
2015-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
CN102441163A
(zh)
|
2005-05-27 |
2012-05-09 |
比奥根艾迪克Ma公司 |
结合tweak的抗体
|
WO2007117264A2
(en)
*
|
2005-08-03 |
2007-10-18 |
Fraunhofer Usa, Inc. |
Compositions and methods for production of immunoglobulins
|
IL172297A
(en)
|
2005-10-03 |
2016-03-31 |
Compugen Ltd |
Soluble vegfr-1 variants for the diagnosis of preeclampsia
|
US20070122408A1
(en)
*
|
2005-10-20 |
2007-05-31 |
The Scripps Research Institute |
Fc Labeling for Immunostaining and Immunotargeting
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
WO2007054816A2
(en)
*
|
2005-11-14 |
2007-05-18 |
Bioren, Inc. |
Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening
|
CN101454461A
(zh)
|
2005-11-16 |
2009-06-10 |
Ambrx公司 |
包括非天然氨基酸的方法和组合物
|
WO2007064919A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
AR057237A1
(es)
|
2005-12-15 |
2007-11-21 |
Genentech Inc |
Metodos y composiciones para actuar sobre la poliubiquitina
|
CN103360496B
(zh)
|
2006-01-05 |
2015-11-18 |
健泰科生物技术公司 |
抗ephb4抗体及其使用方法
|
EP1973945A4
(en)
|
2006-01-16 |
2009-11-18 |
Compugen Ltd |
NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHOD FOR THEIR APPLICATION IN DIAGNOSIS
|
US20070186296A1
(en)
*
|
2006-02-02 |
2007-08-09 |
Wyeth |
Cloning, characterization, and application of tnfrsf19 in neurological disorders
|
US8277816B2
(en)
*
|
2006-02-13 |
2012-10-02 |
Fraunhofer Usa, Inc. |
Bacillus anthracis antigens, vaccine compositions, and related methods
|
KR20080106433A
(ko)
*
|
2006-02-13 |
2008-12-05 |
프라운호퍼 유에스에이, 인코포레이티드 |
인플루엔자 항원, 백신 조성물 및 관련 방법
|
CA2642056A1
(en)
*
|
2006-02-13 |
2007-08-23 |
Fraunhofer Usa, Inc. |
Hpv antigens, vaccine compositions, and related methods
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
WO2007109243A2
(en)
*
|
2006-03-20 |
2007-09-27 |
Duramed Pharmaceuticals, Inc. |
Methods for comparing the immunogenicity of products and uses thereof
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
AU2007249408A1
(en)
*
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
US8148085B2
(en)
|
2006-05-15 |
2012-04-03 |
Sea Lane Biotechnologies, Llc |
Donor specific antibody libraries
|
CN103435697A
(zh)
*
|
2006-05-15 |
2013-12-11 |
航道生物技术有限责任公司 |
流感病毒的中和抗体
|
SG10201501103RA
(en)
|
2006-05-30 |
2015-04-29 |
Genentech Inc |
Antibodies And Immunoconjugates And Uses Therefor
|
AU2007319672B2
(en)
|
2006-06-06 |
2011-06-30 |
Genentech, Inc. |
Anti-DLL4 antibodies and methods using same
|
US20100003189A1
(en)
|
2006-07-14 |
2010-01-07 |
The Regents Of The University Of California |
Cancer biomarkers and methods of use thereof
|
US20090252745A1
(en)
*
|
2006-09-15 |
2009-10-08 |
Duke University |
Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
|
AU2007303572A1
(en)
|
2006-10-02 |
2008-04-10 |
Sea Lane Biotechnologies, Llc |
Design and construction of diverse synthetic peptide and polypeptide libraries
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
AU2008205330B2
(en)
|
2007-01-08 |
2014-07-03 |
Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
SLCO1B3 genotype
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
US9068003B2
(en)
|
2007-01-10 |
2015-06-30 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
BRPI0810865A2
(pt)
*
|
2007-04-28 |
2017-05-09 |
Fraunhofer Usa Inc |
antígenos de tripanossoma, composições vacinais, e métodos relacionados
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
EP2641618A3
(en)
|
2007-07-16 |
2013-10-23 |
Genentech, Inc. |
Humanized anti-CD79B antibodies and immunoconjugates and methods of use
|
AR067544A1
(es)
|
2007-07-16 |
2009-10-14 |
Genentech Inc |
Anticuerpos anti- cd79b e inmunoconjugados y metodos de uso de los mismos
|
WO2009026397A2
(en)
*
|
2007-08-20 |
2009-02-26 |
Fraunhofer Usa, Inc. |
Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
|
US20100239596A1
(en)
*
|
2007-08-22 |
2010-09-23 |
University Of Southern California |
Grp78 and tumor angiogenesis
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP3124497B1
(en)
|
2007-09-14 |
2020-04-15 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
MX369784B
(es)
|
2007-09-26 |
2019-11-21 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
EP2230300A4
(en)
|
2007-10-24 |
2012-08-08 |
Otsuka Chemical Holdings Co Ltd |
POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
|
JP5809415B2
(ja)
|
2007-11-09 |
2015-11-10 |
ペレグリン ファーマシューティカルズ,インコーポレーテッド |
抗vegf抗体の組成物および方法
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
WO2009126350A2
(en)
|
2008-01-18 |
2009-10-15 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
CN107551270A
(zh)
|
2008-04-11 |
2018-01-09 |
中外制药株式会社 |
与多个分子的抗原反复结合的抗原结合分子
|
EP3388527A1
(en)
*
|
2008-05-15 |
2018-10-17 |
Tetherex Pharmaceuticals Corporation |
Anti-psgl-1 antibodies and methods of identification and use
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
JP2009278908A
(ja)
*
|
2008-05-22 |
2009-12-03 |
Fujifilm Corp |
抗オステオカルシン抗体及びそれを用いた免疫測定方法
|
CA2728308A1
(en)
|
2008-06-20 |
2009-12-23 |
Wyeth Llc |
Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
CA2731255C
(en)
*
|
2008-07-21 |
2018-06-05 |
David M. Goldenberg |
Structural variants of antibodies for improved therapeutic characteristics
|
WO2010017598A1
(en)
|
2008-08-14 |
2010-02-18 |
Arana Therapeutics Limited |
Anti-il-12/il-23 antibodies
|
CA2734389A1
(en)
|
2008-08-15 |
2010-02-18 |
Vincent J. Hearing |
S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
|
US20100081575A1
(en)
*
|
2008-09-22 |
2010-04-01 |
Robert Anthony Williamson |
Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
|
EP2352760A2
(en)
*
|
2008-09-22 |
2011-08-10 |
Calmune Corporation |
Methods and vectors for display of 2g12-derived domain exchanged antibodies
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
EP3025727A1
(en)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Methods of treating liver disease
|
JP2012509941A
(ja)
|
2008-11-26 |
2012-04-26 |
ファイブ・プライム・セラピューティクス,インコーポレイテッド |
Serpine2によるコラーゲンおよび平滑筋アクチンの発現を調節するための組成物および方法
|
WO2010061393A1
(en)
|
2008-11-30 |
2010-06-03 |
Compugen Ltd. |
He4 variant nucleotide and amino acid sequences, and methods of use thereof
|
CN101768213B
(zh)
|
2008-12-30 |
2012-05-30 |
中国科学院遗传与发育生物学研究所 |
一种与植物分蘖数目相关的蛋白及其编码基因与应用
|
CN101817879A
(zh)
|
2009-02-26 |
2010-09-01 |
中国科学院遗传与发育生物学研究所 |
金属硫蛋白及其编码基因与应用
|
BRPI1006448B1
(pt)
|
2009-03-25 |
2021-08-17 |
Genentech, Inc |
Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
|
PE20120878A1
(es)
|
2009-04-01 |
2012-08-06 |
Genentech Inc |
ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
|
US20110033389A1
(en)
*
|
2009-04-29 |
2011-02-10 |
Zhifeng Chen |
Modified antibodies for passive immunotherapy
|
CN102459591B
(zh)
*
|
2009-05-20 |
2015-05-13 |
诺维莫尼公司 |
合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
|
KR101805202B1
(ko)
|
2009-05-29 |
2017-12-07 |
모르포시스 아게 |
집합 및 집합의 사용 방법
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
AU2010289400B2
(en)
|
2009-09-02 |
2014-10-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
TW201121566A
(en)
|
2009-10-22 |
2011-07-01 |
Genentech Inc |
Anti-hepsin antibodies and methods using same
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
US20120316071A1
(en)
|
2009-11-04 |
2012-12-13 |
Vaughn Smider |
Methods for affinity maturation-based antibody optimization
|
NZ598901A
(en)
|
2009-11-05 |
2014-08-29 |
Genentech Inc |
Methods and composition for secretion of heterologous polypeptides
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
WO2011084750A1
(en)
|
2009-12-21 |
2011-07-14 |
Genentech, Inc. |
Antibody formulation
|
DK2516465T3
(en)
|
2009-12-23 |
2016-06-06 |
Hoffmann La Roche |
ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
|
US8685524B2
(en)
|
2010-01-29 |
2014-04-01 |
Toray Industries, Inc. |
Polylactic acid-based resin sheet
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
HUE029785T2
(en)
|
2010-02-08 |
2017-04-28 |
Regeneron Pharma |
Common mouse light chain
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
US20120003639A1
(en)
|
2010-04-27 |
2012-01-05 |
Prelude, Inc. |
Cancer biomarkers and methods of use thereof
|
EP2568976B1
(en)
|
2010-05-10 |
2015-09-30 |
Academia Sinica |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
NZ701208A
(en)
|
2010-06-03 |
2016-05-27 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
|
CN103097412B
(zh)
|
2010-07-09 |
2016-08-10 |
克鲁塞尔荷兰公司 |
抗人呼吸道合胞病毒(rsv)抗体以及使用方法
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
CN103260646B
(zh)
|
2010-08-27 |
2016-01-13 |
施特姆森特克斯股份有限公司 |
Notum蛋白调节剂和使用方法
|
NZ608814A
(en)
|
2010-09-03 |
2015-06-26 |
Stem Centrx Inc |
Novel modulators and methods of use
|
CA2810668A1
(en)
|
2010-09-08 |
2012-03-15 |
Halozyme, Inc. |
Methods for assessing and identifying or evolving conditionally active therapeutic proteins
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
KR20140075639A
(ko)
|
2010-10-27 |
2014-06-19 |
더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 |
암 치료법을 위한 e-카드헤린의 가용성 세포외 도메인의 표적화 조성물 및 관련 방법
|
RU2620071C2
(ru)
|
2010-11-17 |
2017-05-22 |
Чугаи Сеияку Кабушики Каиша |
Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
|
US8728981B2
(en)
|
2010-11-19 |
2014-05-20 |
Morphosys Ag |
Collection and methods for its use
|
SG10201601792UA
(en)
|
2010-12-08 |
2016-04-28 |
Stemcentrx Inc |
Novel modulators and methods of use
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
JP6038121B2
(ja)
|
2011-04-21 |
2016-12-07 |
ガーバン インスティテュート オブ メディカル リサーチ |
修飾された可変ドメイン分子及びその製造及び使用の方法b
|
PL3572517T3
(pl)
|
2011-08-05 |
2021-10-04 |
Regeneron Pharmaceuticals, Inc. |
Myszy z humanizowanym uniwersalnym łańcuchem lekkim
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
WO2013045632A1
(en)
|
2011-09-28 |
2013-04-04 |
Era Biotech, S.A. |
Split inteins and uses thereof
|
US20140227724A1
(en)
*
|
2011-09-29 |
2014-08-14 |
Shotaro Tsuji |
Nucleic acid construct for use in screening for peptide antibody, and screening method using same
|
EP2762493B1
(en)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
KR102168733B1
(ko)
|
2011-10-31 |
2020-10-23 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
WO2013106485A2
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
CA2862979A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
EP2817338B1
(en)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3 modulators and methods of use
|
CA2866612C
(en)
|
2012-03-08 |
2018-01-16 |
Halozyme, Inc. |
Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
|
CA2865645A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing immunoglobulin sequences ph-sensitive for antigen building
|
MY173376A
(en)
|
2012-03-16 |
2020-01-21 |
Regeneron Pharma |
Mice that produce antigen?binding proteins with ph?dependent binding characteristics
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
LT3348140T
(lt)
|
2012-03-16 |
2021-01-25 |
Regeneron Pharmaceuticals, Inc. |
Histidinu pakeisti lengvosios grandinės antikūnai ir genetiškai modifikuoti graužikai, išvesti jų gamybai
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
MX360109B
(es)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Metodos y medios para la produccion de moleculas de tipo ig.
|
PT2692865E
(pt)
*
|
2012-07-30 |
2015-02-06 |
Nbe Therapeutics Llc |
Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
|
EP2885311B1
(en)
|
2012-08-18 |
2020-01-01 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
JP6211084B2
(ja)
|
2012-08-21 |
2017-10-11 |
アカデミア シニカAcademia Sinica |
ベンゾシクロオクチン化合物およびその使用
|
JP6490591B2
(ja)
|
2012-12-10 |
2019-03-27 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
抗血液樹状細胞抗原2抗体およびその使用
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
WO2014130879A2
(en)
|
2013-02-22 |
2014-08-28 |
Stem Centrx, Inc. |
Novel antibody conjugates and uses thereof
|
CA2904169C
(en)
|
2013-03-13 |
2021-12-07 |
Genentech, Inc. |
Formulations with reduced oxidation
|
EP2968466B1
(en)
|
2013-03-13 |
2018-07-25 |
F.Hoffmann-La Roche Ag |
Formulations with reduced oxidation
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
WO2014160490A1
(en)
|
2013-03-13 |
2014-10-02 |
Genetech, Inc. |
Antibody formulations
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
WO2014145091A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Cell culture media and methods of antibody production
|
SG10201912621TA
(en)
|
2013-03-15 |
2020-02-27 |
Genentech Inc |
Cell culture compositions with antioxidants and methods for polypeptide production
|
CA2903546A1
(en)
|
2013-03-15 |
2014-09-25 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP3013347B1
(en)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glycan conjugates and use thereof
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
DK3036320T4
(da)
|
2013-08-19 |
2024-05-06 |
Biogen Ma Inc |
Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
|
ES2871418T3
(es)
|
2013-08-28 |
2021-10-28 |
Abbvie Stemcentrx Llc |
Composiciones y métodos de conjugación de anticuerpos específicos de sitio
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
KR102298172B1
(ko)
|
2013-09-06 |
2021-09-06 |
아카데미아 시니카 |
변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
|
EA201600252A1
(ru)
|
2013-09-12 |
2017-05-31 |
Галозим, Инк. |
Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
|
US10611794B2
(en)
|
2013-09-25 |
2020-04-07 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
US11124576B2
(en)
|
2013-09-27 |
2021-09-21 |
Chungai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
BR112016006397B1
(pt)
|
2013-09-27 |
2024-01-16 |
Genentech, Inc |
Formulações de anticorpo de anti-pdl1, seu uso, artigo de fabricação e composição
|
CN105940115B
(zh)
|
2013-11-15 |
2021-07-06 |
巴斯德研究所 |
恶性疟原虫青蒿素耐药性的分子标记物
|
WO2015095809A1
(en)
|
2013-12-20 |
2015-06-25 |
Biogen Idec Ma Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
EP2960252A1
(en)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase for treatment of immunosuppression
|
ES2920677T3
(es)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-VISTA
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US10308721B2
(en)
|
2014-02-21 |
2019-06-04 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
EP3895528A1
(en)
|
2014-03-21 |
2021-10-20 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
EP3122869B2
(en)
|
2014-03-24 |
2022-08-10 |
Biogen MA Inc. |
Methods for overcoming glutamine deprivation during mammalian cell culture
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
US20170022291A1
(en)
|
2014-04-01 |
2017-01-26 |
Adimab, Llc |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
IL248511B
(en)
|
2014-05-13 |
2022-07-01 |
Bavarian Nordic As |
Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
|
KR20220151036A
(ko)
|
2014-05-27 |
2022-11-11 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
EP3149045B1
(en)
|
2014-05-27 |
2023-01-18 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184002A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
WO2016033555A1
(en)
|
2014-08-28 |
2016-03-03 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
JP6899321B2
(ja)
|
2014-09-08 |
2021-07-07 |
アカデミア シニカAcademia Sinica |
糖脂質を使用するヒトiNKT細胞活性化
|
BR112017004393A2
(pt)
|
2014-09-15 |
2018-02-27 |
Genentech Inc |
formulações de anticorpo
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
WO2016073789A2
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
ES2832802T3
(es)
|
2014-11-21 |
2021-06-11 |
Univ Maryland |
Sistemas de administración dirigida del particulado específico de una estructura
|
EP3227687A4
(en)
|
2014-12-05 |
2018-10-24 |
Prelude, Inc. |
Dcis recurrence and invasive breast cancer
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CA2972731A1
(en)
|
2015-01-24 |
2016-07-28 |
Chi-Huey Wong |
Cancer markers and methods of use thereof
|
JP6942633B2
(ja)
|
2015-01-30 |
2021-09-29 |
アカデミア シニカAcademia Sinica |
抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
|
US10858448B2
(en)
|
2015-02-02 |
2020-12-08 |
I2 Pharmaceuticals, Inc. |
Anti-surrogate light chain antibodies
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
CN107438622A
(zh)
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
EP3279216A4
(en)
|
2015-04-01 |
2019-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
|
JP6962819B2
(ja)
|
2015-04-10 |
2021-11-05 |
アディマブ, エルエルシー |
親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
|
US10954515B2
(en)
|
2015-04-21 |
2021-03-23 |
Institut Gustave Roussy |
Therapeutic methods, products and compositions inhibiting ZNF555
|
DK3313882T3
(da)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antistoffer og fragmenter
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
CN108350605A
(zh)
|
2015-09-04 |
2018-07-31 |
台湾浩鼎生技股份有限公司 |
聚糖阵列以及使用方法
|
CA3004288A1
(en)
|
2015-12-28 |
2017-07-06 |
Nobuyuki Tanaka |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
CN115400220A
(zh)
|
2015-12-30 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
CA3007491A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
CA3014013A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス,インコーポレイティド |
NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
EP3433377A4
(en)
|
2016-03-23 |
2019-08-28 |
The General Hospital Corporation |
ASSAYS AND METHOD FOR DETECTING UDP-GLUCOSE
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
CN109311995A
(zh)
|
2016-03-29 |
2019-02-05 |
台湾浩鼎生技股份有限公司 |
抗体、药物组合物和方法
|
WO2017172771A2
(en)
|
2016-03-29 |
2017-10-05 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
|
CA3018936C
(en)
|
2016-04-06 |
2021-10-19 |
Zumutor Biologics, Inc. |
Vectors for cloning and expression of proteins, methods and applications thereof
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
AU2017252128B2
(en)
|
2016-04-22 |
2024-06-06 |
Obi Pharma, Inc. |
Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
|
EP3487880A1
(en)
|
2016-07-25 |
2019-05-29 |
Biogen MA Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
JP2019527690A
(ja)
|
2016-07-27 |
2019-10-03 |
オービーアイ ファーマ,インコーポレイテッド |
免疫原性/治療用グリカン組成物およびその使用
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
TWI764917B
(zh)
|
2016-08-22 |
2022-05-21 |
醣基生醫股份有限公司 |
抗體、結合片段及使用方法
|
IL265144B1
(en)
|
2016-09-06 |
2024-06-01 |
Chugai Pharmaceutical Co Ltd |
Methods for using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
|
MX2019003703A
(es)
|
2016-09-30 |
2020-08-13 |
Janssen Biotech Inc |
Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
|
MA46861A
(fr)
|
2016-11-16 |
2019-09-25 |
Janssen Biotech Inc |
Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
|
JP2019535731A
(ja)
|
2016-11-21 |
2019-12-12 |
オービーアイ ファーマ,インコーポレイテッド |
コンジュゲートさせた生物学的分子、医薬組成物及び方法
|
MX2019008989A
(es)
|
2017-01-30 |
2019-10-09 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
|
AU2017398101A1
(en)
|
2017-02-07 |
2019-08-01 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
AR113142A1
(es)
|
2017-09-29 |
2020-01-29 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
EP3530282A1
(en)
|
2018-02-27 |
2019-08-28 |
Diaccurate |
Therapeutic methods
|
EP3762015A4
(en)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech, Inc. |
METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
|
BR112020018235A2
(pt)
*
|
2018-03-14 |
2020-12-29 |
F. Hoffmann-La Roche Ag |
Métodos para gerar uma biblioteca de polinucleotídeos, bibliotecas de polinucleotídeos, uso de uma biblioteca, método para gerar uma biblioteca de anticorpos e método de seleção de um anticorpo
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
EP3824295A4
(en)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
|
BR112021002130A2
(pt)
|
2018-08-08 |
2021-05-04 |
Genentech, Inc. |
formulação líquida, artigo de fabricação ou kit e método para reduzir a oxidação de um polipeptídeo
|
JP2022500504A
(ja)
|
2018-09-14 |
2022-01-04 |
プレリュード コーポレーションPrelude Corporation |
浸潤性乳癌のリスクを有する対象の治療の選択方法
|
CA3113837C
(en)
|
2018-09-24 |
2022-07-12 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
AU2019354101A1
(en)
|
2018-10-05 |
2021-04-15 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
AU2019385665A1
(en)
|
2018-11-20 |
2021-05-27 |
Bavarian Nordic A/S |
Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40l
|
MX2021005905A
(es)
|
2018-11-20 |
2021-06-23 |
Janssen Biotech Inc |
Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
CA3126654A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
WO2020152544A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
EP3693063A1
(en)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Methods and compositions for treating cancer
|
JP2022525145A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体組成物を生成するための製造方法
|
EP3938390A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
EA202192508A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
MA55283A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de production de compositions d'anticorps anti-tnf
|
CN113853385A
(zh)
|
2019-03-18 |
2021-12-28 |
詹森生物科技公司 |
用抗il12/il23抗体治疗儿科受试者的银屑病的方法
|
JPWO2020213724A1
(ja)
|
2019-04-19 |
2020-10-22 |
|
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
BR112021024425A2
(pt)
|
2019-06-03 |
2022-01-18 |
Janssen Biotech Inc |
Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
|
CA3142580A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
JPWO2021010326A1
(ja)
|
2019-07-12 |
2021-01-21 |
|
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
EP4061406A1
(en)
|
2019-11-20 |
2022-09-28 |
Bavarian Nordic A/S |
Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
BR112023018353A2
(pt)
|
2021-03-12 |
2024-02-06 |
Janssen Biotech Inc |
Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
|
JP2024510588A
(ja)
|
2021-03-12 |
2024-03-08 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
IL309996A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
IL312401A
(en)
|
2021-10-29 |
2024-06-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
CA3238377A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
CA3239216A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|